Jump to content

GW, Almirall may pull cannabis drug in German price row

Recommended Posts

LONDON (Reuters) - GW Pharmaceuticals and Almirall may stop selling the cannabis drug Sativex in Germany after health authorities refused to agree a price that the companies view as acceptable. GW - which developed the under-the-tongue spray as a treatment for spasticity in multiple sclerosis - said on Tuesday the German authorities had determined a price that was significantly lower than in ...


View the full article

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using the community in any way you agree to our Terms of Use and We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.